Top-News
Montag,
05.02.2018 15:00
von
PR Newswire
| Aufrufe: 62
Invictus Receives $16.5 Million from Warrants and Option Exercises Since Dec 22, 2017 and Increases Funded Capacity in 2018 to 27,200 Kg
Mann mit Wirtschaftszeitung (Symbolbild).
pixabay.com
PR Newswire
VANCOUVER, Feb. 5, 2018
VANCOUVER, Feb. 5, 2018 /PRNewswire/ - INVICTUS MD STRATEGIES CORP.'s ("Invictus" or the "Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) is pleased to announce that it has received an additional $16,536,234 from the exercise of previously issued warrants and options since December 22, 2017, bringing Invictus' cash balance to approximately $38 million. A total of 9,658,179 warrants and 26,000 options were exercised for proceeds of $16,527,854 and $10,130 respectively. As a result of such exercises, the Company currently has a total of 89,863,485 common shares issued and outstanding. There are 14,686,743 warrants outstanding that would bring cash into the Company of approximately $26 million, and additionally, 8,518,000 stock options outstanding that would bring in approximately $13.2 million.
Invictus' license holders total annual kilogram capacity after various phases of expansion in 2018 and 2019, complete and in progress, is expected to be approximately 76,400 kg, based on expanding facilities in 2019 to approximately 520,000 square feet. The expected net production capacity to Invictus of approximately 67,000 kg after giving effect to the additional investment as a result of the signed definitive agreement with AB Labs that will bring Invictus' ownership of AB Labs to 50%. With the recent exercise of warrants and options, Invictus' funded capacity today is approximately 27,200 kg.
| Acreage Pharms | Square | Status | % Funded | KG | KG | Forecast | Invictus MD | Invictus MD |
| Phase 1 | 6,600 | Complete | 100% | 160 | 600 | 100% | 600 | 600 |
| Phase 2 | 33,000 | 31-Jan-18 | 100% | - | 4,400 | 100% | 4,400 | 4,400 |
| Phase 3 | 80,000 | 30-Sep-18 | 100% | - | 14,000 | 100% | 14,000 | 14,000 |
| Phase 4 | 80,000 | 1-Mar-19 | 36% | - | 14,000 | 100% | 5,092 | 14,000 |
| Phase 5 | 160,000 | 1-Sep-19 | 0% | - | 28,000 | 100% | - | 28,000 |
| Total Acreage Pharms | 359,600 | | | 160 | 61,000 | | 24,092 | 61,000 |
| AB Laboratories | | | | | | | | |
| Phase 1 | 15,600 | Complete | 100% | 180 | 900 | 50% | 450 | 450 |
| Phase 2 | 40,000 | 15-Jun-18 | 100% | - | 4,000 | 50% | 2,000 | 2,000 |
| Total AB Laboratories | 55,600 | | | 180 | 4,900 | | 2,450 | 2,450 |
| AB Ventures | | | | | | | | |
| Phase 1 | 21,000 | Pre-license | 100% | - | 2,100 | 33% | 700 | 700 |
| Phase 2 Werbung Mehr Nachrichten zur Invictus MD Strategies Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |
